1. Home
  2. TIL vs CYBN Comparison

TIL vs CYBN Comparison

Compare TIL & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TIL
  • CYBN
  • Stock Information
  • Founded
  • TIL 2018
  • CYBN 2019
  • Country
  • TIL United States
  • CYBN Canada
  • Employees
  • TIL N/A
  • CYBN N/A
  • Industry
  • TIL Biotechnology: Pharmaceutical Preparations
  • CYBN Pharmaceuticals and Biotechnology
  • Sector
  • TIL Health Care
  • CYBN Health Care
  • Exchange
  • TIL Nasdaq
  • CYBN Nasdaq
  • Market Cap
  • TIL 177.1M
  • CYBN 176.0M
  • IPO Year
  • TIL 2021
  • CYBN N/A
  • Fundamental
  • Price
  • TIL $27.84
  • CYBN $7.04
  • Analyst Decision
  • TIL Buy
  • CYBN Strong Buy
  • Analyst Count
  • TIL 6
  • CYBN 3
  • Target Price
  • TIL $120.50
  • CYBN $85.00
  • AVG Volume (30 Days)
  • TIL 159.0K
  • CYBN 370.5K
  • Earning Date
  • TIL 08-13-2025
  • CYBN 08-13-2025
  • Dividend Yield
  • TIL N/A
  • CYBN N/A
  • EPS Growth
  • TIL N/A
  • CYBN N/A
  • EPS
  • TIL N/A
  • CYBN N/A
  • Revenue
  • TIL N/A
  • CYBN N/A
  • Revenue This Year
  • TIL N/A
  • CYBN N/A
  • Revenue Next Year
  • TIL N/A
  • CYBN N/A
  • P/E Ratio
  • TIL N/A
  • CYBN N/A
  • Revenue Growth
  • TIL N/A
  • CYBN N/A
  • 52 Week Low
  • TIL $9.90
  • CYBN $4.81
  • 52 Week High
  • TIL $92.00
  • CYBN $13.88
  • Technical
  • Relative Strength Index (RSI)
  • TIL 52.43
  • CYBN 40.31
  • Support Level
  • TIL $25.79
  • CYBN $7.22
  • Resistance Level
  • TIL $29.67
  • CYBN $7.75
  • Average True Range (ATR)
  • TIL 2.62
  • CYBN 0.35
  • MACD
  • TIL 0.10
  • CYBN -0.04
  • Stochastic Oscillator
  • TIL 70.92
  • CYBN 5.44

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Share on Social Networks: